Oragenics (NYSE:OGEN) Coverage Initiated at StockNews.com

Research analysts at StockNews.com began coverage on shares of Oragenics (NYSE:OGEN) in a note issued to investors on Saturday. The firm set a “sell” rating on the stock.

Oragenics Stock Performance

Shares of Oragenics stock opened at $0.19 on Friday. Oragenics has a 52-week low of $0.18 and a 52-week high of $3.43. The company has a fifty day moving average of $0.27 and a 200-day moving average of $0.32. The stock has a market capitalization of $4.02 million, a price-to-earnings ratio of -0.03 and a beta of 0.87.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.